BlissCo Gets License Amendment to Add Cannabis Oil Production

BlissCo Cannabis (CSE:BLIS) announced it got an amendment to its Health Canada license to include the production of cannabis oil.

As quoted in the press release:

“Being only the 38th independent company to earn a cannabis oil production license is a testament to our team and the high standard that we hold our work to. This cannabis oil production license will allow us to continuously innovate and develop new cannabis products that our patients and adult use clients can enjoy healthily and confidently,” said Damian Kettlewell, CEO of BlissCo Cannabis Corp.

The amount of cannabis oil sold to medical patients in Canada has increased 91.7 [percent] throughout the past year.

BlissCo’s cannabis extraction lab is fully operational and features a MIDAS XII Co2  extraction system, which ensures that the team at BlissCo can focus on extracts that offer therapeutic  terpenes with Full Spectrum oils, offering the Whole Plant approach to each patient.

“We intend to use these high-quality extractions to develop a diverse range of cannabis oil products including [tetrahydrocannabinol] THC and [cannabidiol] CBD tinctures, capsules and sublingual sprays for the medical market,” added Kettlewell.

Click here to read the full press release.